No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
Operating as a Contract Development and Manufacturing Organization (CDMO), ST Pharm Co. Ltd. provides pharmaceutical and non-pharmaceutical products within South Korea. Its comprehensive Chemistry, Manufacturing, and Controls (CMC) services include the development of analytical methods, in-house reference standard testing, qualification and validation of analytical techniques, detailed analytical characterization, and robust CMC documentation. The company also specializes in oligonucleotide-based products, such as antisense oligonucleotides, siRNA, miRNA, aptamers, CpG, and decoy molecules, as well as monomers and phosphoramidites. Additionally, ST Pharm manufactures generic Active Pharmaceutical Ingredients (APIs) for a broad range of therapeutic areas, including anti-cancer, anti-coagulant, anti-fungal, anti-hyperlipidemia, anti-hypertensive, anti-tuberculosis, asthma, COPD, cough suppression, diabetes mellitus, epilepsy, hepatitis B, and erectile dysfunction medications, along with ingredients for MRI contrast agents. Beyond its pharmaceutical focus, the firm supplies components for secondary batteries, electronic materials, and polymer catalysts. Founded in 1983 as Samchully Pharmaceutical Company Ltd., ST Pharm Co. Ltd. is headquartered in Seoul, South Korea.
www.stpharm.co.krNo one on the platform currently holds 237690.KQ.
No tracked institution reports a position in 237690.KQ as of their last filing.
No one on the platform has traded 237690.KQ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 7.9% | 4.8% | — | — | — | |
| Rev. Growth % | 21.1% | 21.7% | ||||
| Profit Margin % | 16.6% | 9.1% | 5.9% | |||
| Free Cash Flow Margin % | -8.9% | -12.5% | -11.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $417.9B | +27.0% | $3293.33 | $2740.70–$3656.89 | — | 9 |
| 2027 | $523.7B | +25.3% | $4516.11 | $3870.53–$5474.29 | — | 10 |
| 2028 | $631.5B | +20.6% | $5783.00 | $5197.57–$6745.36 | — | 5 |
| 2029 | $791.5B | +25.3% | $0.00 | $0.00–$0.00 | — | 4 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 2 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-02-10 | $343.46 | $638.25 | +85.8% |
| 2024-11-01 | $228.54 | $750.00 | +228.2% |
| $34350.00 |
| -0.72% |
| $1.31T |
| — |
| 068760.KQCelltrion Pharm, Inc. | $39000.00 | -0.64% | $1.73T | — |
| 069620.KSDaewoong pharmaceutical Co.,Ltd | $108500.00 | -1.18% | $1.25T | — |
Source: Financial Modeling Prep · peers by sector/industry